Letter to the shareholders
Dear shareholders, dear friends,
It's been a year of review - on our 85th anniversary, we looked back to enjoy our successes, to thank the people with whome we've achieved them and celebrate with everyone we want to share our future with. Thank you for sharing!
We are proud to have been among the pioneers with two major initiatives - we have distributed shares to all our employees according to their length of service and contribution to the company's successes and distributed the first interim dividend. We have received support from our shareholders for both initiatives, which has always been an important indication for us confirming that we are doing the right thing.
Sopharma Group has gone through a difficult path of integration of the newly acquired companies Lekovit in Serbia and the pharmacies chain PharmaStore in Bulgaria, as well as of the merged company Unipharm.
After the exceptionally strong 2017, we kept the growth rates of consolidated sales revenue, but we slowed down on net profit. In achieving synergy with newly acquired and merged companies, we expect optimization of the operating and net results over the next two years and ratios closer to those of 2017.
We hope for your support and trust!
Ognian Donev, PhD
Chairman of the Board of Directors and Executive Director of Sopharma AD
Key Financial Results
|Deprecation and amortization (EBITDA)||72,278||85,944||16.7%|
|Operating profit/Sales revenue||3.3%||5.5%|
|Net profit/Sales revenue||2.6%||4.5%|
|Net debt/EBITDA, annualized||4.15x||3.02x|
Extraordinary General Meeting of Shareholders took place
General Meeting of Shareholders was held regularly and a decision was taken to distribute bonus shares among all employees on the occasion of the 85th anniversary of Sopharma AD
An Extraordinary General Meeting of the Shareholders was held and a decision was taken for the transformation by merger of Unipharm AD into Sopharma AD
An Extraordinary General Meeting of the Shareholders was held and a decision was made for the first payment of an interim dividend
More than 10,000 employees, partners and friends celebrated 85th anniversary of Sopharma AD in Arena Armeec, Sofia
An Annual Investor Relations Meeting was held with the management of Sopharma AD and Sopharma Trading AD and a visit to the Regional Distribution Center of Sopharma Trading AD Automated with the KNAPP System
New Development and Products
with marketing authorizations for the period January - December 2017. Marketing authorizations for three new products have been issued.
Amlodipine tablets 5 mg
Amlodipine tablets 10 mg
Expected in 2018
Three to six new products are expected to be introduced by the end of the 2018.
Over 30 production processes and technologies are in the processes of transfer, validation and optimization. Pharmaceutical development is carried out of 4 new medicinal products and one active substance.